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Abstract
The presence of amyloid aggregates of the 42 amino acid peptide of amyloid beta (Ab42) in the brain is the characteristic
feature of Alzheimer’s disease (AD). Amyloid beta (Ab deposition is also found in muscle fibers of individuals affected by
inclusion body myositis (sIBM), a rare muscular degenerative disease affecting people over 50. Both conditions are presently
lacking an effective therapeutic treatment. There is increasing evidence to suggest that natural polyphenols may prevent
the formation of toxic amyloid aggregates; this applies also to oleuropein aglycone (OLE), the most abundant polyphenol in
extra virgin olive oil, previously shown to hinder amylin and Ab aggregation. Here we evaluated the ability of OLE to
interfere with Ab proteotoxicity in vivo by using the transgenic CL2006 and CL4176 strains of Caenorhabditis elegans,
simplified models of AD and of sIBM, which express human Ab in the cytoplasm of body wall muscle cells. OLE-fed CL2006
worms displayed reduced Ab plaque deposition, less abundant toxic Ab oligomers, remarkably decreased paralysis and
increased lifespan with respect to untreated animals. A protective effect was also observed in CL4176 worms but only when
OLE was administered before the induction of the Ab transgene expression. These effects were specific, dose-related, and
not mediated by the known polyphenolic anti-oxidant activity, suggesting that, in this model organism, OLE interferes with
the Ab aggregation skipping the appearance of toxic species, as already shown in vitro for Ab42.
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia,
affecting a large proportion of aged people in the developed
countries, where its social impact and burden on national health
budgets are severe [1]. The key histopathological sign of AD is the
presence, in several brain areas, of intracellular neurofibrillary
tangles of hyperphosphorylated tau and of minute extracellular
amyloid deposits (plaques) around cerebral vessels and dystrophic
and degenerating neurites [2,3]. The main component of the
plaques is a polymeric fibrillar form of one out of a family of 39–43
amino acid variants (particularly the 42 amino acid peptide, Ab42)
of a peptide generated by proteolysis of the membrane amyloid
precursor protein (AbPP) [4]. The presently accepted ‘‘amyloid
cascade hypothesis’’ states that the functional alterations and
behavioral deficits that characterize AD result primarily from the
presence of these plaque deposits [5]. More recently, the interest in
deciphering the relation between plaque burden, tissue functional
impairment and neuronal death has focused on the importance, as
the main toxic species to neurons, of the oligomeric pre-fibrillar
assemblies originating at the onset of peptide polymerization into
fibrils [6–10]. It has also been proposed that intraneuronal Ab
may play a crucial role in the early progression of AD [11];
accordingly, the focus of the research into molecules able to delay
AD occurrence and to relieve its symptoms has shifted from
hindering fibril growth to avoiding the appearance of toxic
oligomeric intermediates.
Ab deposits and oligomers are also found in inclusion body
myositis (sIBM), a musculoskeletal pathology which, while rare, is
the most frequent degenerative condition progressively affecting
muscular apparatus in patients over 50. The pathology displays a
progressive muscle weakness and atrophy resulting in severe
disability [12]. Biopsy analysis of the diseased tissue shows
vacuolated muscle fibers containing deposits of ubiquitin-positive
aggregates of misfolded proteins, including Ab and phosphorylat-
ed tau, which display amyloid signatures, together with remark-
able inflammation, similar to AD and other neurodegenerative
pathologies [13,14]. The importance of Ab levels for disease
development and progression of muscle degeneration was also
supported by a study on transgenic mice engineered so as to
produce increased amounts of Ab42 in the muscle tissue [15].
In spite of the intense efforts of the international research aimed
at unraveling the pathophysiology of cell degeneration and tissue
functional impairment, AD and sIBM still remain diseases without
an effective therapy. Nevertheless, many molecules have been
investigated as possible drugs useful in relieving AD occurrence
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and symptoms [16,17], and some of them entered clinical trials. At
present, the search of therapeutically exploitable molecules also
focuses on dietary regimens epidemiologically associated with
reduced risk of developing AD or with significant delay in the
appearance of AD symptoms in the aged population. Mounting
evidence supports the idea that the Mediterranean diet (MD), rich
in polyphenols, is greatly beneficial for the prevention of age-
related dysfunctions as well as of several diseases, including cancer
and cardiovascular events, cerebrovascular disease, stroke and
neurodegenerative diseases [18–21], notably vascular dementia
and AD. Studies in rodents have found that foods rich in
polyphenols, particularly those present in wine and in extra virgin
olive oil (EVOO), improve deficits in learning and memory
associated with aging and disease, reverse oxidative damage in the
brain [22,23] and attenuate AD-like pathology and cognitive
deterioration in the Tg2576 AD mouse model [24].
Natural phenolic substances, a vast array of molecules found in
many plants and foods of vegetal origin, can hinder amyloid
aggregation in several ways; most of them (epigallocatechin gallate,
oleocanthal, curcumin, oleuropein aglycone (OLE), resveratrol,
ellagic acid, tannic acid) display the ability to prevent the
appearance of those pre-fibrillar aggregates considered the most
toxic amongst amyloid species both in cultured cells [25–31] and
in animal models [32–34]. A number of studies, including the
‘‘Three city study’’ [35] have clearly shown a strict association
between most of the protective effects of the MD and the sustained
consumption of EVOO, a basic component of the MD. In
particular, a number of polyphenols and secoiridoids found in
EVOO, including oleocanthal, hydroxythyrosol and OLE, have
been considered potential candidates as key responsible of the
protective effect of EVOO [30,31,36,37]. Oleuropein (the
glycoside of OLE) is a main constituent of the leaves and
unprocessed olive drupes of Olea europaea, and most of the phenolic
molecules found in olive oil or table olives result from spontaneous
oleuropein hydrolysis and processing. Oleuropein hydrolysis is
carried out by an endogenous b-glycosidase during olive ripening
and in the technological process of olive oil production and
releases the aglycone moiety of the molecule in the oil [38]. The
finding that oleuropein associates with the Aß peptide into a non-
covalent complex [36,39] supports our recent data showing that
OLE interferes with the in vitro aggregation of human amylin and
Ab42, skipping the appearance of toxic oligomers and promoting
peptide aggregation into aggregates devoid of cytotoxicity [30,40].
Here we report an in vivo study on OLE protection against Ab42
aggregation in tissue, which generates the plaque deposits found in
AD and in sIBM, using C. elegans as a simplified invertebrate model
of AD [41,42] and, possibly, of sIBM. In particular, we used the
CL2006 transgenic C. elegans strain, constitutively expressing
cytoplasmic human Ab3–42 in the body wall muscle cells [41,42].
This strain displays an age-related progressive reduction of muscle-
specific motility which is related to the accumulation of both Ab3–
42 fibrils and oligomers [17], for this reason, it has already been
used to demonstrate the protective effect of several treatments,
including the Gingko biloba extract EGb 761 and tetracyclines,
against Ab toxicity in vivo [43–48]. We show that, unlike CL2006
worms grown on normal medium, those grown on OLE-
supplemented medium are protected against plaque deposits, Ab
oligomer appearance and the resulting impairment of motility, as
well as displaying increased survival.
Our results support the possibility that dietary supplementation
with OLE can be beneficial against sIBM and AD by reducing
plaque burden as well as by delaying the occurrence and reducing
the severity of symptoms.
Materials and Methods
Materials
Tetracycline hydrochloride was from Fluka (Switzerland) and n-
acetyl-cysteine (NAC) was from Sigma Aldrich (Switzerland). All
drugs were freshly dissolved in water before use. Oleuropein was
from Extrasynthese (Lyon, France). Almond b-glycosidase
(EC3.2.1.21) was from Fluka (Sigma-Aldrich, Steinheim, Ger-
many). Oleuropein deglycosylation by b-glycosidase was per-
formed as described [40]. The complete deglycosylation was
confirmed by assaying the glucose released in the supernatant with
the Glucose (HK) Assay Kit (Sigma). GC-MS (gas cromatography-
mass spectrometry) analysis showed the absence of any oleuropein
in the precipitate and the substantially total recover of OLE in the
same precipitate. A 100 mM stock solution of OLE was made in
dimethyl sulfoxide (DMSO); dilutions in aqueous buffers were
made immediately before use.
C. elegans strains
The N2 ancestral strain, the transgenic CL2006 strain, the
temperature-inducible transgenic nematode strain CL4176 and
the control CL802 strain were used [41,42]. CL2006 constitutively
produces Ab3–42 in the body-wall muscles, while the expression of
muscle-specific Ab1–42 in CL4176 depends on raising the
temperature from 16 to 24 uC. The transgenic arrays in the
CL2006, CL4176 and CL802 strains all contain the dominant
mutant collagen [rol-6 (su 1066)] as morphological marker. All
nematode strains were obtained from the Caenorhabditis Genetic
Center (University of Minnesota, USA) and were propagated at
16 uC on solid Nematode Growth Medium (NGM) seeded with E.
coli (OP50) for food. To prepare age-synchronized animals, the
nematodes were transferred to fresh NGM plates on reaching
maturity at 3 days of age and allowed to lay eggs overnight.
Isolated hatchlings from the synchronized eggs (day 1) were
cultured on fresh NGM plates at 16 uC.
Paralysis assay
The N2 wild type strain, and the CL2006 and CL802 worms,
after egg synchronization, were placed at 16 uC on fresh NGM
plates (35610 mm culture plates, 100 worms/plate) seeded with
OP50 E. coli. At L1, L2 or L3 larval stage, the worms were fed with
different concentrations of OLE (12.5–500 mM, 100 ml/plate) and
paralysis was evaluated at L4 larval stage. The worms that did not
move or only moved their head when gently touched with a
platinum loop were scored as paralyzed. Tetracycline was used as
positive control. To this end, egg-synchronized CL2006 worms
placed on tetracycline-resistant E. coli at 16 uC were fed, at L3
larval stage, with 50 mM tetracycline and the paralysis was scored
after 24 h [48].
CL4176, after egg synchronization, were placed on fresh NGM
plates (35610 mm culture plates, 100 worms/plate) seeded with
E. coli for 54 h at 16 uC. To induce the transgene expression, the
temperature was raised from 16 to 24 uC. Worms were treated
with vehicle or OLE (50–500 mM, 100 ml/plate) 30 h before
(corresponding to L1 larval stage), 6 h before (corresponding to L2
larval stage) or 18 h after the temperature shift (corresponding to
L3 larval stage) (Figure S1A). The effect of repeated administration
of 50–100 mM OLE at L1, L2 and L3 was also determined. The
paralysis was scored 42 h after the temperature induction.
Tetracycline, at 50 mM, was administered 18 h after temperature
rise, as positive control, and the paralysis was scored 24 h after
treatment [48].
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Lifespan
Gravid CL2006 and CL802 worms were allowed to lay eggs for
6–8 h to produce an age-synchronized population which was
cultured at 16 uC. At L2 larval stage, the worms were fed with
vehicle or with 50–100 mM OLE. In some experiments, a second
administration of OLE was performed after 8 days. Once the
worms reached adulthood (at reproductive maturity), they were
transferred daily to fresh NGM plates seeded with OP50, in the
absence of fluorodeoxyuridine, until they stopped laying eggs. To
avoid overlapping generations, the worms were then transferred
every day until all nematodes were dead. The number of worms
paralyzed (considered dead) was scored starting from 48 h after
treatment, at L4 larval stage (day 0), and for each consecutive day
until all worms were dead.
Fluorescence staining of b-amyloid
Age-synchronized CL2006 worms, either fed or not fed with
OLE as described above, were fixed in 4% paraformaldehyde in
PBS, pH 7.4, for 24 h at 4 uC. The nematodes were stained with
1.0 mM 1,4-bis(3-carboxy-hydroxy-phenylethenyl)-benzene (X-
34), in 10 mM Tris-HCl buffer, pH 8.0, a dye specific for amyloid
aggregates, for 4 h at room temperature [48]. The samples were
then destained, mounted on slides for microscopy and observed
with an inverted fluorescence microscope (IX-71 Olympus); the
images were acquired using a CDD camera. Amyloid deposits in
the anterior area of worms fed with vehicle (n = 20) and OLE
(n = 20) were quantified by counting the number of X-34 positive
spots and were expressed as Ab deposits/anterior area.
Ab expression and content of toxic oligomers in
transgenic CL2006
Transgenic worms, fed with vehicle or with 50 mM OLE, were
collected by washing the plates with M9 buffer; the suspension was
transferred to tubes, centrifuged at 11006g for 4 min and washed
twice to eliminate the bacteria. The worm pellet was then
resuspended in lysis buffer (5.0 mM NaCl, 5.0 mM EDTA,
1.0 mM dithiothreitol (DTT) and protease inhibitor mixture in
25 mM Tris/HCl buffer, pH 7.5) and homogenized using a
TeSeE homogenizer (Bio-Rad) with acid-washed glass beads
(Sigma) [48]. The proteins were then precipitated overnight with
methanol (1:4/vol:vol ) at 220 uC, before being resuspended in
loading buffer. Equal amounts (5–10 mg) were then spotted onto
nitrocellulose membranes (Millipore). A 0.1% Ponceau Red
solution (Sigma Aldrich) was used to stain the blotted membranes
for total protein visualization. After blocking with PBS plus 0.1%
(v/v) Tween 20, the membranes were incubated overnight either
with an anti-Ab mouse monoclonal antibody (Clone WO2,
1:1000, Millipore) or with the A11 mouse monoclonal antibody
(1:1000, Biosource), which specifically recognizes toxic Ab pre-
fibrillar oligomers. Peroxidase-conjugated anti-mouse IgG (1:5000,
Sigma) was used as the secondary antibody. The mean volumes of
immunoreactive spots and of Red Ponceau dyed spots were
analyzed using the Progenesis SameSpots software (Nonlinear
Dynamics, UK). The data were expressed as the mean of the
volume of the immunoreactive spot/volume of total Ponceau dyed
proteins in the spot 6SD.
Superoxide production
Age-synchronized CL2006 or CL802 worms were placed on
NGM plates seeded with E. coli at 16 uC for 48 h and then fed, at
L2 larval stage, with vehicle or with 50 mM OLE for 48 h (100 ml/
plate). As positive controls, worms were placed at 16 uC for 72 h,
and then fed with 50 mM tetracycline or with 5.0 mM NAC for
24 h. The worms were collected into 1.6 ml of 1.0% Tween 20 in
PBS and subjected to sonication using the Sonopuls Ultrasonic
homogenizer (Bandelin, Germany) to break up the outer cuticle.
50 nM phorbol myristate acetate (PMA) and 1.8 mM Nitro Blue
Tetrazolium (NBT) (Sigma Aldrich) were then added to the
suspension. After incubation at 37 uC for 30 min, sample
absorbance was measured at 560 nm using the Infinite M200
multifunctional micro-plate reader (Tecan, Austria). The protein
content was determined using a Bio-Rad Protein assay (Bio-Rad
Laboratories GmbH, Munchen, Germany). Results are calculated
as absorbance units/mg of protein and expressed as % of control,
i.e. the percentage of superoxide produced with respect to vehicle
treated CL2006 worms.
Statistical analysis
The effects of vehicle and drug on cultured worms were
compared by an independent Student’s t-test or One-way
ANOVA test, and the IC50 was determined using Prism version
4.0 for Windows (GraphPad Software, CA, USA). A p,0.05 was
considered statistically significant.
Results
We have previously reported that OLE reduces Ab aggregation
in vitro and hinders the appearance of oligomeric pre-fibrillar
aggregates, thus protecting the exposed cells against Ab injury
[30]. Here we checked whether OLE was also effective in vivo by
investigating whether it protected the CL2006 strain against Ab3–
42 toxicity. The worms, synchronized and placed on E. coli at
16 uC, were fed with either vehicle or OLE (12.5–500 mM,
100 ml/plate), starting at L1, L2 or L3 larval stages. Worm
paralysis was rated 96, 48 or 24 h later, when the worms were at
L4 (see Fig. 1A for treatment schedule). N2 wild type strain and
CL802 worms, in which the Ab transgene was not expressed and
the paralysis did not occur [43], were used as controls. We found
that OLE protected CL2006 worms from the paralysis induced by
Ab expression and aggregation in a dose-dependent manner upon
administration either at L2 or L3, supporting a specific effect
induced by OLE (Fig.1B, C). The IC50 value, i.e. the drug
concentration that inhibited paralysis by 50%, calculated after
OLE administration at L2 larval stage, was 14.561.0 mM
(n = 100 worms/group, mean6SE). This value was significantly
lower (p,0.01, Student’s t test) than that determined after OLE
administration at L3 (24268.5 mM, n = 100 worms/group,
mean6SE).
Feeding CL2006 worms at L1 larval stage with 50 mM OLE
produced a protective effect significantly lower than that occurring
when the same dose of drug was administered at L2 (45.8% vs.
65% reduction of paralysis for L1 and L2 administration,
respectively, p,0.01, Student’s t test) (Fig. 1D) The protective
effect at L1 did not increase by feeding worms with 100 mM OLE
(46% protection of paralysis) and higher doses resulted to be toxic,
causing the death of worms.
The protective effect of 50 mM OLE at L2 larval stage was
similar to that occurring when 500 mM of drug was administered
at L3; in fact, worm paralysis was reduced by 65.0% and 62.6%
respectively (Fig.1D). The OLE effect was comparable to that
obtained feeding CL2006 worms with 50 mM tetracycline at L3
(Fig. 1D), which resulted in a reduction of nematode paralysis of
66%. The effect of tetracycline when administered at L2 was not
here considered due to the toxicity of the drug at this larval stage
[48]. The double administration of 50 mM OLE both at L2 and
L3 larval stage did not further improve drug protection; the
Oleuropein Aglycone Protects from Ab Toxicity
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reduction of the paralysis was comparable to that observed with
the single administration at L2 (data not shown).
The feeding of CL802 worms and wild type N2 nematodes with
OLE starting at L1 (50–100 mM), L2 or L3 larval stages (12.5–
500 mM), did not modify their viability (Fig. 1B, C, D) indicating
that the drug did not cause any aspecific and/or toxic effects in
control strains.
We also investigated whether OLE protected CL4176 worms
from the paralysis caused by the inducible Ab1–42 expression [48].
According to the treatment schedule set out in Figure S1A, worms
were fed either vehicle or OLE (50–500 mM, 100 ml/plate) 30 h
before the temperature rise (at L1 larval stage), 6 h before the
temperature rise (at L2) or 18 h after the rise of temperature (at
L3). A slight reduction of the paralysis of CL4176 worms was
observed only when nematodes fed 50–100 mM OLE 30 h before
Figure 1. Effect of OLE on Ab-induced paralysis in CL2006 transgenic C. elegans strain. (A) Diagram illustrating the paralysis assay showing
when the drug was administered and when the paralysis assay was scored. (B–C) Dose-response effect of OLE on the paralysis induced by Ab
expression in CL2006 and CL802 transgenic worms. Egg-synchronized worms were placed at 16 uC on fresh NGM plates seeded with OP50 E. coli and,
at L2 (B) or L3 (C) stage, were fed with OLE (12.5–500 mM). The number of paralyzed worms was scored 48 h or 24 h after treatment (at L4 larval
stage) for L2- and L3-treated worms, respectively. Data are shown as percentage6SE of paralyzed worms to vehicle treated ones (n = 100 worms/
group, 3 independent assays). (D) Percentage of paralyzed worms fed with OLE. CL2006, CL802 and N2 worms, cultured as above, were fed 50 mM
OLE at L1 or L2 and 500 mM at L3. Tetracycline at 50 mM was administered at L3 as positive control. The number of paralyzed worms was scored at L4
larval stage. Data are shown as percentage6SD of paralyzed worms to vehicle treated ones (n = 100 worms/group, 3 independent assays). uu
p,0.01 vs. CL802, **p, 0.01 vs CL2006 worms fed with vehicle (One-way ANOVA test), and +p,0.01 vs. CL2006 worms fed with 50 mM OLE at L2
(Student’s t test).
doi:10.1371/journal.pone.0058893.g001
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the induction of the Ab expression (reduction of paralysis of 18%)
(Fig. S1) whereas the other treatment schedules were ineffective
(data not shown). Feeding CL4176 at L1 larval stage with OLE at
doses higher than 100 mM, as well as the repeated administration
of 50–100 mM OLE starting from L1, resulted to be toxic.
These findings indicated that the OLE protective effect was
lower in CL4176 strain than in CL2006 worms: this could be
ascribed to the fully penetrant paralysis phenotype of the inducible
strain. The optimal protective effect of OLE against Ab-induced
paralysis was obtained in CL2006, when drug feeding started from
L2 larval stage, and in CL4176 when the drug was administered
from L1. These observations indicated that OLE protective effect
was maximal when worms were treated from the beginning of the
aggregation process.
We then investigated whether OLE reduced the degree of Ab
amyloidosis in CL2006 transgenic worms by evaluating the
amount of aggregate deposits in their head region [49]. The
worms, synchronized and placed at 16 uC for 48 h at L2, were fed
either vehicle or OLE (50 mM, 100 ml/plate) for 48 h and then
stained with the X-34 dye which recognizes b-amyloid aggregates
[50]. OLE strongly reduced X-34 positive spots (Fig. 2A–B),
indicating that the drug inhibited Ab fibril deposition.
It is known that compounds able to interact with protein fibrils
and aggregates affect age-related changes in protein homeostasis
and extend worm lifespan [17]. Accordingly, we analyzed the
effect of OLE administration on overall CL2006 and CL802
nematode survival. Feeding CL2006 worms at L2 larval stage with
50 mM OLE significantly increased their median survival by 47%
(Fig. 2C) (median survival: 7 and 15 days for worms fed with
vehicle or with OLE, respectively. p = 0.004, Log-rank test). The
same effect on survival was observed after administration of a
higher dose of OLE (100 mM) (median survival: 7 and 15 days for
worms fed with vehicle or with OLE, respectively. p = 0.003, Log-
rank test). In addition, the survival of CL2006 worms exposed to a
double administration of 50 mM OLE, at L2 and 8 days after, was
not different from that of nematodes receiving a single dose of the
drug (median survival: 15 days for either worms fed one or two
OLE doses. p = 0.790, Log-rank test).
The administration of 50 mM OLE at L2 larval stage to CL802
nematodes did not modify their survival (Fig. 2D) (median survival:
12 and 13 days for worms fed vehicle or OLE, respectively. p
= 1.000 Log-rank test) supporting the absence of aspecific effects.
Such beneficial effects of OLE were not related to its ability to
modify the steady-state of Ab by interfering with its production
and/or degradation. In fact no significant difference in the Ab
immunoreactive signal was observed between worms fed with
vehicle or with 50 mM OLE at L2 larval stage, as indicated by the
dot blot analysis performed on CL2006 worm lysates using an
antibody specific for total Ab (WO2) (Fig. 3A, B). It is known that
the expression of Ab in paralyzed CL2006 worms is accompanied
by an increase of the A11-positive oligomer production [48]. We
therefore performed dot blot analysis to determine whether the
protective effect of OLE could be related to its ability to counteract
Ab oligomer formation. Actually, it transpired that, in nematodes
fed with 50 mM OLE at L2 larval stage, the A11-immunoreactivity
was reduced by 40% compared with that found in CL2006 worms
treated with vehicle (p,0.05, n = 9, Student’s t-test) (Fig. 3C, D).
The increased production of superoxide precedes the paralysis
in the transgenic C. elegans CL2006 strain constitutively expressing
the human Ab3–42 peptide [45,46]; this was observed under
experimental conditions (+64% of superoxide production in
CL2006 worms as compared to the CL802 control strain.
p,0.001, Student’s t-test, n = 100 worms/group). In the same
strain, the protective effect of tetracyclines and of a Ginko biloba
extract against worm paralysis was found to be associated with a
reduced superoxide production [48,49]. An in vitro and in vivo
ROS-scavenging effect of chronic OLE treatment has been
reported as well [51] and this is a likely explanation for its ability
to reduce lipid peroxidation. We then investigated whether,
besides the previously described anti-fibrillogenic effect, an
antioxidant action contributed to OLE protection against Ab
toxicity. To this end, CL2006 worms were fed with vehicle or with
50 mM OLE at L2 larval stage, followed after 48 h by superoxide
measurement. We found that OLE treatment did not reduce the
level of intracellular superoxide, whereas a significant reduction by
37% and 31% with respect to vehicle-fed worms, was observed in
nematodes treated for 24 h with antioxidant compounds such as
5.0 mM NAC or 50 mM tetracycline, respectively (Fig. 4). We
conclude that the protective effect of OLE in Ab-expressing worms
is not related to its antioxidant activity. This matches the
conclusion reached when we investigated OLE protection against
Ab and amylin aggregates in cultured cells [30,40].
Overall, our data show that OLE treatment of the C. elegans
CL2006 strain at early larval stage is significantly effective against
Ab oligomerization, fibrillization and aggregate deposition,
without a significant reduction in Ab levels. The strongly reduced
extent of plaque deposition and oligomer level results in a strong
protection against the pathological phenotype, such that the
worms recover good motility and viability and improve their
survival with respect to those fed with vehicle.
Discussion
Interest in amyloid diseases has increased since it has become
clear that this classification encompasses several pathologies.
These pathologies affect different tissues and organs with various
outcomes, but are all characterized by the presence of toxic
protein aggregates. Such diseases typically manifest after a very
long period of asymptomatic development; for this reason great
attention is being paid to the identification of dietary regimens and
diet components that can provide prevention or at least delay the
onset and reduce the severity of the disease. In this respect, many
studies have investigated the MD, with particular focus on red
wine and EVOO, which were identified as important sources of
polyphenolic substances with clear anti-aggregation power [25–
34]. Our recent research on OLE, the main polyphenolic
component of EVOO, corroborates such expectations. In fact,
we found that OLE, once introduced in the peptide aggregation
mixture, blocks the in vitro formation of toxic pre-fibrillar oligomers
of both human amylin and Ab11–42, eventually leading to the
generation of harmless protofibrils and poorly structured higher
order aggregates [30,40].
However, the data on OLE from our and other laboratories
came only from in vitro experiments using cultured cells as a
biological model; accordingly, the next necessary step was to prove
OLE efficacy in a living organism. We chose C. elegans for several
reasons: in spite of its great simplicity (it is made of 959 somatic
cells, it lacks a circulatory system and a central nervous system, but
302 of its cells are neurons), 60% of its genes are homologous to
human ones and 12 out of its 17 signal transduction pathways are
conserved in humans. It has a very short generation time (from egg
to egg in 3–4 days), thus producing numerous clonal progeny, and
a short lifespan that, for the CL2006 transgenic strain, hardly
exceeds two weeks. In this strain the deposition of amyloid
aggregates of Ab3–42 in the muscles is age-dependent (as it is in
man) and leads to the paralysis of the worm, a phenotype which
can be easily and clearly scored.
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By using this model we confirmed that OLE can protect against
amyloid toxicity not only in vitro, but also in vivo. In CL2006
worms, constitutively expressing Ab protein, the activity of OLE in
preventing the amyloid-induced paralysis was specific, dose- and
time-dependent (its IC50 was significantly lower when treatment
started at L2 rather than at L3). A little protective effect was also
observed on the paralysis caused in CL4176 worms by the
temperature-induced Ab aggregation, but only when OLE was
administered before the induction of transgene expression.
These results agrees with those obtained in vitro and show that
cell viability is maximally preserved when the aggregating peptide
is exposed to OLE from the beginning of the aggregation process.
This suggests that the main action of OLE consists in hindering
the formation of toxic oligomeric species [30], probably through a
direct interaction with the monomeric peptide. In turn, the
significant reduction of the level of toxic oligomers relieves the
animal from their toxic effects. Actually, it is increasingly
recognized that oligomer toxicity results, at least in part, from
their interaction with the cell membrane, with membrane
alterations and disassembly resulting in derangement of the
selective ion permeability [52]. Our interpretation was further
confirmed by the observation that A11 immunoreactivity (given by
the presence of toxic pre-fibrillar oligomers) was significantly
reduced in OLE-fed CL2006 worms compared to the vehicle-
treated ones. Moreover, the analysis of fibrillar deposits in the
whole worm with the X-34 dye, which recognizes b-amyloid
Figure 2. OLE reduces amyloid deposition and extends the life-span of CL2006 transgenic C. elegans strain. Egg-synchronized CL2006
worms were placed at 16 uC on fresh NGM plates seeded with OP50 E.coli and, at L2 larval stage, were fed with vehicle or with 50 mM OLE for 48 h.
(A) At 120 h of age, corresponding to day 1 of adult age, worms were stained with X-34 dye. The staining of amyloid plaques on whole-mount and
fixed samples was visualized at short wavelength excitation. Scale bar 20 mm. Arrows in red indicate amyloid deposits. (B) Amyloid deposits in the
anterior area of worms fed with vehicle (n = 20) and OLE (n = 20), quantified by counting the number of X-34 positive spots. **p,0.01 vs. CL2006
worms fed with vehicle (Student’s t test). (C–D) Kaplan-Meier survival curves of (C) CL2006 and (D) CL802 worms fed with vehicle or with 50 mM OLE
at L2 larval stage. The number of paralyzed worms (considered dead) was scored 48 h after treatment, at L4 larval stage (day 0 in graph) and every
consecutive day, until all worms were dead. Survival is expressed as a percentage of the initial population. Plots are representative of three
independent experiments (n = 30 worms/group).
doi:10.1371/journal.pone.0058893.g002
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aggregates but not oligomers [50], showed the complete absence of
plaques in OLE-fed animals. This was well beyond our
expectations since OLE was not able to prevent the in vitro
deposition of some pre-fibrillar material [30,40]. The complexity
of the cellular environment, much greater than that present inside
a test tube, seems to improve OLE inhibitory activity, extending it
beyond the inhibition of oligomer formation. By showing the
absence in OLE fed worms of fibrillar deposits and the reduction
of oligomeric assemblies, all with no reduction of total Ab content,
our results suggest that Ab homeostasis is maintained by non-
degradative pathways. Interestingly, a single administration of
OLE is enough to achieve the maximal protective response; in
fact, repeated treatments neither further inhibited worm paralysis
nor prolonged their survival. In addition, we found that the dose of
OLE needed to obtain the same effects as the 50 mM at L2 was
increased by ten times at L3 (Fig. 1D). It is proposed that the dose
of OLE needed to maintain reduced oligomer levels and worm
viability increases with age as far as the tendency of the Ab peptide
to aggregate, due to the presence of previously-formed tiny
aggregates or seeds. A possible explanation of the fact that a
further administration of OLE after that at L2 is redundant could
be that OLE remains in the cells for prolonged periods, even when
the worms are transferred to new culture plates that do not contain
the drug, making any further OLE implementation ineffective.
Our survival data agree with this view. In fact, CL2006 survival
was significantly increased after a single OLE administration at
L2, whereas a second administration, 8 days later (i.e. in the
middle of the lifespan), did not further improve the result.
OLE, like all polyphenols, has antioxidant properties, and
reactive oxygen species production is a typical outcome of amyloid
deposition. Other molecules that were shown to be effective as
inhibitors of amyloid deposition and paralysis in CL2006 strain,
like tetracyclines, also induced a reduction of superoxide
production [48]. However, this anti-oxidant effect was not seen
in OLE-fed worms. This result confirms our idea that the
beneficial effect of OLE cannot be traced back to its antioxidant
properties. In fact, if cultured cells are concomitantly exposed to
toxic amyloid aggregates and to OLE, their viability is not
recovered. Actually the protection occurs only when cells are
exposed to aggregates grown in the presence of OLE [30,40], thus
devoid of toxic oligomeric species. The results obtained in this
invertebrate model confirm that, as show for other polyphenols, a
Figure 3. Effect of OLE on Ab oligomer production. Representative dot blot of (A) total Ab (WO2) and (C) Ab oligomers (A11) in CL2006
transgenic worms fed with vehicle or with 50 mM OLE at L2 larval stage. Equal amounts of proteins from worm lysates (5 mg) were spotted in
triplicate. Total proteins on the blotted membranes were stained using a 0.1% Red Ponceau solution and were used to normalize the immuno-
specific signal for protein loading. The mean volume of the Ab-reactive and Red Ponceau-dyed spots was determined using the Progenesis
SameSpots software (Nonlinear Dynamics, UK). Immunoreactivity of WO2 (B) or A11 (D), from three independent experiments (n = 9), was expressed
as the mean volume of the immunoreactive band/volume of Ponceau-dyed proteins6SD.*p,0.05 vs. vehicle (Student’s t-test).
doi:10.1371/journal.pone.0058893.g003
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key aspect of OLE protection against amyloid toxicity results from
its anti-aggregation properties [25,29,53,54]. Notice that, in these
transgenic C. elegans strains, the oxidative stress performs a minor
role in amyloid toxicity. In fact L-ascorbic acid treatment, which
reduces superoxide levels, has no protective effect on the paralysis
phenotype [43], which is mainly determined by Ab oligomeriza-
tion.
Conclusions
OLE, the main polyphenol of EVOO, is capable of interfering
with the toxic amyloid aggregation of Ab not only in vitro, but also
in vivo in an invertebrate model of AD and sIBM. OLE-fed worms
showed a reduced paralysis and a prolonged lifespan. Though
further research is needed to clarify the exact molecular and
cellular mechanisms underlying OLE protective activity, our
results suggest that, at least in our experimental model, OLE does
not alter the rate of production and degradation of Ab nor acts as
an antioxidant; rather, it seems to directly interfere with the
aggregation process inhibiting the formation of soluble toxic
oligomers and amyloid fibrils, as has already been observed in vitro.
Supporting Information
Figure S1 Effect of OLE on Ab-induced paralysis in
CL4176 transgenic C. elegans strain. (A) Diagram illustrat-
ing the paralysis assay performed in CL4176 worms, showing
when the OLE was administered, when the temperature was
increased and when the paralysis was determined. (B) Percentage
of paralyzed worms fed with 50–100 mM OLE 30 h before the
temperature increase (corresponding to L1 larval stage). Egg-
synchronized CL4176 worms were placed at 16 uC on fresh NMG
plates seeded with OP50 E. coli and, at L1 were fed with vehicle or
OLE (50–100 mM). Tetracycline at 50 mM, was administered at
L3 as positive control. The number of paralyzed worms was scored
42 h after temperature induction. Data are shown as percenta-
ge6SD of paralyzed worms to vehicle treated ones
(n = 100 worms/group, 3 independent assays). *p,0.05 and
**p,0.01 vs. CL4176 worms fed with vehicle (One-way ANOVA
test).
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